Cipla Of India Markets Generic of Bayer's Kidney Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
India's Cipla has launched at home a generic version of Nexavar (sorafenib) marketed by Germany's Bayer to treat kidney cancer
You may also be interested in...
Sharing "Schering" Link Gets Bayer And Cadila To Talk Joint Venture; Deal Spanning Market To Manufacturing Likely In Final Stages
MUMBAI - Germany-headquartered agrichemicals-to-healthcare behemoth Bayer is talking to India's Cadila Healthcare to form an equal stake joint venture that will revolve around selling its own branded and generic products as well as contracting out a significant part of its manufacturing requirements
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.